Table 1.
COVID-19 patients’ characteristics.
| Patient characteristics | All patients (n = 62) | Moderate patients (n = 35) | Severe patients (n = 27) | p |
|---|---|---|---|---|
| Sociodemographic data | ||||
| Sex | ||||
| Male. N (%) | 33 (53) | 18 (51) | 15 (56) | 0.747 |
| Female. N (%) | 29 (47) | 17 (49) | 12 (44) | 0.747 |
| Age. Years (SD) | 69.7 (16.9) | 68.5 (18.5) | 71.3 (14.9) | 0.500 |
| Race | ||||
| Caucasic. N (%) | 52 (84) | 28 (80) | 24 (89) | 0.345 |
| Hispanic. N (%) | 10 (16) | 7 (20) | 3 (11) | 0.345 |
| Medical history | ||||
| AH. N (%) | 35 (56) | 18 (51) | 17 (63) | 0.364 |
| DM. N (%) | 19 (31) | 9 (26) | 10 (37) | 0.338 |
| DL. N (%) | 32 (52) | 17 (49) | 15 (56) | 0.585 |
| Chronic obstructive pulmonary disease. N (%) | 14 (23) | 9 (26) | 5 (19) | 0.502 |
| Cardiovascular disease. N (%) | 22 (35) | 11 (31) | 11 (41) | 0.447 |
| Chronic renal disease. N (%) | 7 (11) | 2 (6) | 5 (19) | 0.114 |
| Chronic liver disease. N (%) | 3 (5) | 2 (6) | 1 (4) | 0.715 |
| Malignancy. N (%) | 6 (10) | 2 (6) | 4 (15) | 0.229 |
| Clinical data | ||||
| Pneumonia. N (%) | 42 (68) | 21 (60) | 21 (78) | 0.138 |
| Hemoglobin. g/dL (SD) | 12.3 (2.2) | 12.4 (2.4) | 12.1 (1.9) | 0.516 |
| Leucocytes.103/μL (SD) | 6.4 (2.6) | 6.2 (2.1) | 6.7 (3.1) | 0.499 |
| Neutrophils. 103/μL (SD) | 4.5 (2.6) | 3.9 (1.9) | 5.3 (3.2) | 0.064 |
| Linfocytes.103/μL (SD) | 1.3 (0.8) | 1.5 (0.7) | 1.0 (0.8) | 0.009** |
| CPR. mg/dL (SD) | 4.4 (6.2) | 1.6 (1.9) | 7.9 (8.0) | <0.001** |
| Ferritin. ng/mL (SD) | 581.0 (1324.6) | 299.3 (336.6) | 946.2 (1929.5) | 0.096 |
| D-dimer. ng/mL (SD) | 1397.1 (2622.9) | 1381.0 (3131.7) | 1417.4 (1851.2) | 0.955 |
| Fibrinogen. mg/dL (SD) | 580.0 (186.4) | 532.0 (177.1) | 642.1 (182.9) | 0.021* |
| LDH. U/L (SD) | 512.2 (206.6) | 460.3 (155.7) | 579.4 (245.2) | 0.033* |
| IL-6. pg/mL (SD) | 31.3 (50.5) | 10.8 (15.0) | 53.2 (64.7) | 0.002** |
| Treatment | ||||
| Hydroxychloroquine. N (%) | 41 (66) | 22 (63) | 19 (70) | 0.535 |
| Ritonavir/lopinavir. N (%) | 12 (19) | 5 (14) | 7 (26) | 0.141 |
| Glucocorticoids. N (%) | 19 (31) | 4 (11) | 15 (56) | <0.001** |
| Tocilizumab. N (%) | 4 (6) | 0 (0) | 4 (15) | 0.019 |
| Anti-inflammatory treatment. N (%) | 22 (35) | 5 (14) | 17 (63) | <0.001** |
| Clinical outcome | ||||
| Recovery. N (%) | 57 (92) | 35 (100) | 22 (81) | 0.007** |
| Death. N (%) | 5 (8) | 0 (0) | 5 (19) | 0.007** |
SD: Standard deviation; AT: Arterial hypertension; DM: Diabetes mellitus; DL: dislypidemia; CRP: C-reactive protein; LDH: lactate dehydrogenase; IL-6: interleukin 6.